GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » Cyclically Adjusted PB Ratio

Fennec Pharmaceuticals (Fennec Pharmaceuticals) Cyclically Adjusted PB Ratio : 17.48 (As of May. 01, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Fennec Pharmaceuticals's current share price is $9.09. Fennec Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.52. Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 17.48.

The historical rank and industry rank for Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FENC' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 9.21   Med: 16.8   Max: 23.75
Current: 17.91

During the past years, Fennec Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 23.75. The lowest was 9.21. And the median was 16.80.

FENC's Cyclically Adjusted PB Ratio is ranked worse than
95.5% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs FENC: 17.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Fennec Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $-0.430. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.52 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Fennec Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.76 20.21 9.33 19.78 21.59

Fennec Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.78 15.73 17.62 14.18 21.59

Competitive Comparison of Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Fennec Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=9.09/0.52
=17.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Fennec Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.43/129.4194*129.4194
=-0.430

Current CPI (Dec. 2023) = 129.4194.

Fennec Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 -0.444 99.695 -0.576
201406 -0.473 100.560 -0.609
201409 -0.327 100.428 -0.421
201412 0.058 99.070 0.076
201503 0.078 99.621 0.101
201506 0.102 100.684 0.131
201509 0.093 100.392 0.120
201512 0.050 99.792 0.065
201603 0.022 100.470 0.028
201606 0.341 101.688 0.434
201609 0.309 101.861 0.393
201612 0.262 101.863 0.333
201703 0.210 102.862 0.264
201706 0.619 103.349 0.775
201709 0.559 104.136 0.695
201712 1.453 104.011 1.808
201803 1.388 105.290 1.706
201806 1.323 106.317 1.610
201809 1.197 106.507 1.455
201812 1.071 105.998 1.308
201903 0.965 107.251 1.164
201906 0.828 108.070 0.992
201909 0.754 108.329 0.901
201912 0.597 108.420 0.713
202003 0.425 108.902 0.505
202006 1.425 108.767 1.696
202009 1.208 109.815 1.424
202012 1.118 109.897 1.317
202103 0.959 111.754 1.111
202106 0.857 114.631 0.968
202109 0.731 115.734 0.817
202112 0.606 117.630 0.667
202203 0.481 121.301 0.513
202206 0.328 125.017 0.340
202209 0.107 125.227 0.111
202212 -0.097 125.222 -0.100
202303 -0.278 127.348 -0.283
202306 -0.367 128.729 -0.369
202309 -0.399 129.860 -0.398
202312 -0.430 129.419 -0.430

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fennec Pharmaceuticals  (NAS:FENC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Fennec Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (Fennec Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Robert Andrade officer: Chief Financial Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Rosty Raykov director, officer: Chief Executive Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Adrian Haigh director 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Marco Maria Brughera director VIALE STEFINI 14, MILANO L6 00000
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel officer: Chief Commercial Officer 1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp 10 percent owner 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook director PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040